These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33740373)

  • 1. Repurposing Infectious Disease Hits as Anti-
    Hulverson MA; Choi R; McCloskey MC; Whitman GR; Ojo KK; Michaels SA; Somepalli M; Love MS; McNamara CW; Rabago LM; Barrett LK; Verlinde CLMJ; Arnold SLM; Striepen B; Jimenez-Alfaro D; Ballell L; Fernández E; Greenwood MN; Las Heras L; Calderón F; Van Voorhis WC
    ACS Infect Dis; 2021 May; 7(5):1275-1282. PubMed ID: 33740373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum.
    Nava MG; Calderón F; Fernández E; Ballell L; Bamborough P; Vinayak S
    Microbiol Spectr; 2023 Feb; 11(1):e0387422. PubMed ID: 36533912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
    Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.
    Bessoff K; Sateriale A; Lee KK; Huston CD
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1804-14. PubMed ID: 23380723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box.
    Bessoff K; Spangenberg T; Foderaro JE; Jumani RS; Ward GE; Huston CD
    Antimicrob Agents Chemother; 2014 May; 58(5):2731-9. PubMed ID: 24566188
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Dhal AK; Pani A; Yun SI; Mahapatra RK
    J Biomol Struct Dyn; 2021 Sep; 39(15):5461-5470. PubMed ID: 32633680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
    Huang W; Choi R; Hulverson MA; Zhang Z; McCloskey MC; Schaefer DA; Whitman GR; Barrett LK; Vidadala RSR; Riggs MW; Maly DJ; Van Voorhis WC; Ojo KK; Fan E
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533246
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel acyl carbamates and acyl / diacyl ureas show in vitro efficacy against Toxoplasma gondii and Cryptosporidium parvum.
    Li K; Grooms GM; Khan SM; Hernandez AG; Witola WH; Stec J
    Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():80-90. PubMed ID: 33011650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.
    Janes J; Young ME; Chen E; Rogers NH; Burgstaller-Muehlbacher S; Hughes LD; Love MS; Hull MV; Kuhen KL; Woods AK; Joseph SB; Petrassi HM; McNamara CW; Tremblay MS; Su AI; Schultz PG; Chatterjee AK
    Proc Natl Acad Sci U S A; 2018 Oct; 115(42):10750-10755. PubMed ID: 30282735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.
    Castellanos-Gonzalez A; White AC; Ojo KK; Vidadala RS; Zhang Z; Reid MC; Fox AM; Keyloun KR; Rivas K; Irani A; Dann SM; Fan E; Maly DJ; Van Voorhis WC
    J Infect Dis; 2013 Oct; 208(8):1342-8. PubMed ID: 23878324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
    Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
    Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
    Hulverson MA; Vinayak S; Choi R; Schaefer DA; Castellanos-Gonzalez A; Vidadala RSR; Brooks CF; Herbert GT; Betzer DP; Whitman GR; Sparks HN; Arnold SLM; Rivas KL; Barrett LK; White AC; Maly DJ; Riggs MW; Striepen B; Van Voorhis WC; Ojo KK
    J Infect Dis; 2017 Apr; 215(8):1275-1284. PubMed ID: 28329187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum.
    Khan SM; Garcia Hernandez A; Allaie IM; Grooms GM; Li K; Witola WH; Stec J
    Int J Parasitol Drugs Drug Resist; 2022 Aug; 19():6-20. PubMed ID: 35462232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
    Morales Gomez MA
    Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth
    Funkhouser-Jones LJ; Ravindran S; Sibley LD
    mBio; 2020 Mar; 11(2):. PubMed ID: 32127445
    [No Abstract]   [Full Text] [Related]  

  • 16. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.
    Jumani RS; Bessoff K; Love MS; Miller P; Stebbins EE; Teixeira JE; Campbell MA; Meyers MJ; Zambriski JA; Nunez V; Woods AK; McNamara CW; Huston CD
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases.
    Guo F; Zhang H; McNair NN; Mead JR; Zhu G
    J Infect Dis; 2018 Mar; 217(7):1110-1117. PubMed ID: 29300993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nullscript inhibits Cryptosporidium and Toxoplasma growth.
    Murakoshi F; Bando H; Sugi T; Adeyemi OS; Nonaka M; Nakaya T; Kato K
    Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():159-166. PubMed ID: 33120250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
    Li K; Nader SM; Zhang X; Ray BC; Kim CY; Das A; Witola WH
    PLoS Pathog; 2019 Jul; 15(7):e1007953. PubMed ID: 31356619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.
    Guo F; Zhang H; Fritzler JM; Rider SD; Xiang L; McNair NN; Mead JR; Zhu G
    J Infect Dis; 2014 Apr; 209(8):1279-87. PubMed ID: 24273180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.